See more : Sonoro Energy Ltd. (SNV.V) Income Statement Analysis – Financial Results
Complete financial analysis of West Pharmaceutical Services, Inc. (WST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of West Pharmaceutical Services, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Surana Solar Limited (SURANASOL.NS) Income Statement Analysis – Financial Results
- Triton International Limited (TRTN) Income Statement Analysis – Financial Results
- Danske Bank A/S (DNSKF) Income Statement Analysis – Financial Results
- Fukuoka Financial Group, Inc. (FKKFY) Income Statement Analysis – Financial Results
- Optiemus Infracom Limited (OPTIEMUS.BO) Income Statement Analysis – Financial Results
West Pharmaceutical Services, Inc. (WST)
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.95B | 2.89B | 2.83B | 2.15B | 1.84B | 1.72B | 1.60B | 1.51B | 1.40B | 1.42B | 1.37B | 1.27B | 1.19B | 1.10B | 1.06B | 1.05B | 1.02B | 913.30M | 699.70M | 541.60M | 490.70M | 419.70M | 396.90M | 430.10M | 469.10M | 449.70M | 452.50M | 458.80M | 412.90M | 365.10M | 348.70M | 338.20M | 329.60M | 323.20M | 308.70M | 288.20M | 253.30M | 235.60M | 190.10M |
| Cost of Revenue | 1.82B | 1.75B | 1.66B | 1.38B | 1.23B | 1.17B | 1.09B | 1.01B | 944.00M | 973.60M | 933.70M | 878.70M | 853.00M | 786.60M | 752.10M | 748.50M | 728.30M | 651.50M | 507.10M | 385.70M | 334.90M | 302.10M | 280.80M | 289.70M | 289.10M | 282.20M | 288.50M | 302.00M | 265.10M | 225.90M | 222.10M | 217.80M | 221.40M | 221.50M | 206.70M | 197.40M | 174.40M | 160.20M | 128.00M |
| Gross Profit | 1.13B | 1.14B | 1.18B | 767.80M | 605.70M | 545.40M | 512.60M | 501.10M | 455.80M | 447.80M | 434.70M | 387.70M | 339.30M | 318.10M | 303.60M | 302.60M | 291.80M | 261.80M | 192.60M | 155.90M | 155.80M | 117.60M | 116.10M | 140.40M | 180.00M | 167.50M | 164.00M | 156.80M | 147.80M | 139.20M | 126.60M | 120.40M | 108.20M | 101.70M | 102.00M | 90.80M | 78.90M | 75.40M | 62.10M |
| Gross Profit Ratio | 38.28% | 39.36% | 41.52% | 35.76% | 32.92% | 31.76% | 32.06% | 33.21% | 32.56% | 31.50% | 31.77% | 30.61% | 28.46% | 28.80% | 28.76% | 28.79% | 28.61% | 28.67% | 27.53% | 28.79% | 31.75% | 28.02% | 29.25% | 32.64% | 38.37% | 37.25% | 36.24% | 34.18% | 35.80% | 38.13% | 36.31% | 35.60% | 32.83% | 31.47% | 33.04% | 31.51% | 31.15% | 32.00% | 32.67% |
| Research & Development | 68.40M | 58.50M | 52.80M | 46.90M | 38.90M | 40.30M | 39.10M | 36.80M | 34.10M | 37.30M | 37.90M | 33.20M | 29.10M | 23.90M | 19.90M | 18.70M | 16.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 262.90M | 242.60M | 239.80M | 233.00M | 228.70M | 234.90M | 218.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 353.40M | 316.90M | 362.80M | 302.00M | 272.70M | 262.90M | 242.60M | 239.80M | 233.00M | 228.70M | 234.90M | 218.10M | 191.10M | 187.70M | 177.70M | 159.30M | 152.50M | 155.90M | 120.30M | 105.20M | 111.00M | 82.60M | 73.40M | 67.70M | 77.90M | 70.50M | 70.20M | 72.80M | 69.90M | 69.00M | 63.50M | 57.10M | 85.00M | 57.80M | 45.60M | 41.50M | 32.20M | 29.90M | 26.60M |
| Other Expenses | 31.50M | 26.80M | 7.90M | 12.00M | 2.40M | 4.80M | -2.00M | -27.70M | -60.10M | 200.00K | 500.00K | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 454.00M | 402.20M | 423.50M | 360.90M | 311.60M | 303.20M | 281.70M | 276.60M | 267.10M | 266.00M | 272.80M | 251.30M | 221.70M | 213.30M | 197.60M | 191.90M | 168.60M | 160.80M | 121.70M | 106.70M | 94.30M | 81.00M | 71.90M | 104.70M | 113.60M | 102.80M | 102.10M | 103.50M | 99.50M | 92.10M | 85.50M | 80.70M | 109.50M | 80.50M | 65.90M | 60.40M | 49.00M | 44.60M | 38.60M |
| Cost & Expenses | 2.27B | 2.15B | 2.08B | 1.74B | 1.55B | 1.48B | 1.37B | 1.28B | 1.21B | 1.24B | 1.21B | 1.13B | 1.07B | 999.90M | 949.70M | 940.40M | 896.90M | 812.30M | 628.80M | 492.40M | 429.20M | 383.10M | 352.70M | 394.40M | 402.70M | 385.00M | 390.60M | 405.50M | 364.60M | 318.00M | 307.60M | 298.50M | 330.90M | 302.00M | 272.60M | 257.80M | 223.40M | 204.80M | 166.60M |
| Interest Income | 28.00M | 5.10M | 1.00M | 1.40M | 3.80M | 2.10M | 1.30M | 1.10M | 1.60M | 3.50M | 1.90M | 1.80M | 1.30M | 600.00K | 800.00K | 1.40M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.00M | 7.90M | 7.20M | 6.80M | 4.70M | 6.30M | 6.50M | 7.00M | 12.50M | 13.00M | 15.10M | 14.90M | 18.20M | 16.80M | 14.40M | 16.00M | 14.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 137.30M | 120.60M | 122.30M | 109.10M | 103.40M | 104.40M | 96.70M | 90.70M | 89.90M | 90.00M | 85.20M | 76.90M | 75.70M | 73.20M | 68.10M | 60.60M | 56.60M | 52.70M | 47.40M | 33.20M | 33.00M | 33.00M | 32.00M | 37.00M | 35.70M | 32.30M | 31.90M | 30.70M | 29.60M | 23.10M | 22.00M | 23.60M | 24.50M | 22.70M | 20.30M | 18.90M | 16.80M | 14.70M | 12.00M |
| EBITDA | 844.10M | 887.90M | 895.20M | 531.70M | 399.40M | 355.30M | 335.90M | 319.60M | 220.00M | 273.30M | 249.00M | 200.00M | 183.40M | 161.30M | 166.40M | 186.10M | 157.50M | 149.90M | 122.90M | 94.50M | 84.80M | 82.80M | 74.70M | 75.90M | 102.10M | 97.00M | 93.80M | 84.00M | 77.90M | 70.20M | 63.10M | 63.30M | 23.20M | 43.90M | 56.40M | 49.30M | 46.70M | 45.50M | 35.50M |
| EBITDA Ratio | 28.62% | 29.60% | 31.02% | 24.09% | 21.73% | 14.38% | 14.31% | 13.04% | 9.19% | 12.80% | 11.87% | 11.20% | 10.53% | 10.76% | 9.95% | 10.65% | 20.40% | 18.01% | 19.39% | 15.68% | 17.28% | 18.56% | 19.55% | 21.39% | 21.49% | 28.13% | 20.38% | 22.47% | 18.29% | 19.56% | 17.95% | 18.72% | 6.71% | 14.91% | 16.94% | 16.20% | 19.31% | 18.34% | 16.99% |
| Operating Income | 676.00M | 734.00M | 752.30M | 406.90M | 296.60M | 240.30M | 228.90M | 196.80M | 128.60M | 182.00M | 162.40M | 135.10M | 109.60M | 90.70M | 97.50M | 124.10M | 94.90M | 101.00M | 72.20M | 48.20M | 54.50M | 26.70M | 41.30M | 35.70M | 66.40M | 64.70M | 61.90M | 53.30M | 48.30M | 47.10M | 41.10M | 39.70M | -1.30M | 21.20M | 36.10M | 30.40M | 29.90M | 30.80M | 23.50M |
| Operating Income Ratio | 22.92% | 25.43% | 26.57% | 18.95% | 16.12% | 13.99% | 14.31% | 13.04% | 9.19% | 12.80% | 11.87% | 10.67% | 9.19% | 8.21% | 9.24% | 11.81% | 9.30% | 11.06% | 10.32% | 8.90% | 11.11% | 6.36% | 10.41% | 8.30% | 14.15% | 14.39% | 13.68% | 11.62% | 11.70% | 12.90% | 11.79% | 11.74% | -0.39% | 6.56% | 11.69% | 10.55% | 11.80% | 13.07% | 12.36% |
| Total Other Income/Expenses | 22.00M | -54.10M | -3.40M | -5.60M | -4.80M | 400.00K | -3.40M | -5.40M | -12.50M | -13.00M | -15.30M | -26.50M | -23.20M | -31.50M | -14.40M | -15.10M | -8.50M | -16.50M | -12.00M | -8.20M | -7.50M | -9.50M | -13.40M | -11.10M | -9.30M | -36.80M | -4.20M | -26.10M | -5.70M | -6.40M | -4.30M | -5.70M | -2.50M | -10.50M | -2.20M | -2.90M | -6.70M | -600.00K | 1.90M |
| Income Before Tax | 698.00M | 679.90M | 748.90M | 401.30M | 291.80M | 240.70M | 222.40M | 189.80M | 116.10M | 169.00M | 147.10M | 108.60M | 92.70M | 74.50M | 83.10M | 109.50M | 86.40M | 84.50M | 45.20M | 41.20M | 47.00M | 17.20M | 27.80M | 3.10M | 57.10M | 27.90M | 57.70M | 27.20M | 42.60M | 40.70M | 36.80M | 34.00M | -3.80M | 10.70M | 33.90M | 27.50M | 23.20M | 30.20M | 25.40M |
| Income Before Tax Ratio | 23.66% | 23.55% | 26.45% | 18.69% | 15.86% | 14.02% | 13.91% | 12.58% | 8.29% | 11.89% | 10.75% | 8.58% | 7.77% | 6.74% | 7.87% | 10.42% | 8.47% | 9.25% | 6.46% | 7.61% | 9.58% | 4.10% | 7.00% | 0.72% | 12.17% | 6.20% | 12.75% | 5.93% | 10.32% | 11.15% | 10.55% | 10.05% | -1.15% | 3.31% | 10.98% | 9.54% | 9.16% | 12.82% | 13.36% |
| Income Tax Expense | 122.30M | 114.70M | 107.20M | 72.50M | 59.00M | 41.40M | 80.90M | 54.40M | 26.30M | 47.20M | 40.20M | 32.70M | 23.50M | 13.60M | 13.50M | 23.70M | 17.20M | 24.60M | -400.00K | 11.10M | 16.70M | 4.10M | 8.60M | 1.50M | 18.40M | 21.20M | 13.30M | 10.80M | 13.90M | 13.40M | 14.30M | 14.30M | 4.70M | 6.40M | 13.20M | 10.10M | 9.50M | 13.20M | 10.40M |
| Net Income | 593.40M | 585.90M | 661.80M | 346.20M | 241.70M | 206.90M | 150.70M | 143.60M | 95.60M | 127.10M | 112.30M | 80.70M | 75.50M | 65.30M | 72.60M | 86.00M | 70.70M | 67.10M | 45.60M | 19.40M | 31.90M | 18.40M | -5.20M | 1.60M | 38.70M | 6.70M | 44.40M | 16.40M | 28.70M | 27.30M | 23.50M | 19.70M | -8.50M | 4.30M | 20.70M | 17.40M | 13.70M | 17.00M | 15.00M |
| Net Income Ratio | 20.12% | 20.30% | 23.37% | 16.13% | 13.14% | 12.05% | 9.42% | 9.52% | 6.83% | 8.94% | 8.21% | 6.37% | 6.33% | 5.91% | 6.88% | 8.18% | 6.93% | 7.35% | 6.52% | 3.58% | 6.50% | 4.38% | -1.31% | 0.37% | 8.25% | 1.49% | 9.81% | 3.57% | 6.95% | 7.48% | 6.74% | 5.82% | -2.58% | 1.33% | 6.71% | 6.04% | 5.41% | 7.22% | 7.89% |
| EPS | 7.99 | 7.88 | 8.90 | 4.68 | 3.27 | 2.80 | 2.04 | 1.96 | 1.33 | 1.79 | 1.61 | 1.19 | 1.12 | 0.98 | 1.11 | 1.33 | 1.08 | 1.05 | 0.75 | 0.57 | 0.75 | 0.33 | -0.09 | 0.03 | 0.65 | 0.10 | 0.67 | 0.25 | 0.43 | 0.43 | 0.37 | 0.32 | -0.14 | 0.07 | 0.32 | 0.27 | 0.21 | 0.27 | 0.24 |
| EPS Diluted | 7.88 | 7.73 | 8.67 | 4.57 | 3.21 | 2.74 | 1.99 | 1.91 | 1.30 | 1.75 | 1.57 | 1.15 | 1.08 | 0.95 | 1.06 | 1.25 | 1.02 | 1.00 | 0.71 | 0.56 | 0.75 | 0.33 | -0.09 | 0.03 | 0.64 | 0.10 | 0.67 | 0.25 | 0.43 | 0.43 | 0.37 | 0.31 | -0.14 | 0.07 | 0.32 | 0.27 | 0.21 | 0.27 | 0.24 |
| Weighted Avg Shares Out | 74.30M | 74.40M | 74.40M | 73.90M | 74.00M | 73.90M | 73.90M | 73.30M | 72.00M | 70.90M | 69.60M | 68.00M | 67.40M | 66.60M | 65.60M | 64.80M | 65.40M | 64.40M | 62.20M | 60.00M | 58.00M | 57.80M | 57.34M | 57.63M | 59.66M | 65.74M | 65.90M | 65.67M | 66.23M | 64.22M | 63.51M | 62.54M | 61.82M | 63.70M | 64.69M | 65.05M | 64.47M | 64.15M | 63.16M |
| Weighted Avg Shares Out (Dil) | 75.30M | 75.80M | 76.30M | 75.80M | 75.40M | 75.40M | 75.80M | 75.00M | 73.80M | 72.80M | 71.40M | 71.80M | 74.00M | 73.40M | 72.60M | 72.20M | 72.40M | 67.20M | 65.00M | 61.60M | 58.20M | 57.80M | 57.39M | 57.64M | 60.19M | 66.02M | 66.29M | 65.67M | 66.23M | 64.22M | 63.95M | 63.04M | 61.82M | 63.70M | 65.20M | 65.05M | 64.47M | 64.15M | 63.16M |
West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
West Pharmaceutical Q2'24 results missed expectations, with lower revenues and EPS missing guidance, impacted by destocking and poor sales in various segments. Management remains optimistic for the back half of the year, with capital investments to support growth, but cash...
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
West Pharmaceutical Services (WST) Q2 Earnings and Revenues Miss Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.52 per share, missing the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.11 per share a year ago.
West Pharmaceutical lowers full-year sales, profit forecast on subdued demand
West Pharmaceutical Services cut its annual profit and sales forecast on Thursday, on lower demand for its medical equipment used in making injectable drugs as biotech customers worked through their existing inventories.
West Announces Second-Quarter 2024 Results
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
The Secret's Out - 3 Fantastic Dividend Growth Stocks You Need To Know
Stocks outperform cash, but most wealth comes from a few standout companies. More than half of individual stocks lose money long-term, highlighting the need for careful selection. Investors can build wealth with stocks offering essential products and steady growth. Success...
24 Barron's Pro-Picked 2024 Mid-Year Dividend Dogs: Buy 2 In July
Barron's Mid-Year 2024 Pro Picks revealed by panelists for potential investment opportunities. Barron's interviews of eleven financial industry Roundtable-pros tapped 48 predictions. Twelve non-ADR foreign stocks and six funds were dropped by YCharts screens, and six selections paid no dividends,...
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
West to Host Second-Quarter 2024 Conference Call
EXTON, Pa. , July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25,...
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Source: https://incomestatements.info
Category: Stock Reports
What were West Pharmaceutical’s net sales in Q3 2024?
(NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%. Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.